Abiopharma

🔍 Lin Xichen (Executive)

Company: Structure Therapeutics Inc. (GPCR)

Report Date: 2026-09-01

Detailed Transactions and Holdings:

• Acquired 17,817 shares of Ordinary Shares at $0.34 per share (Direct)
  Date: 2026-09-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 246,777.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 17,817 shares of Ordinary Shares (Direct)
  Date: 2026-09-01 | Code: C | equity_swap_involved: 0 | shares_owned_after: 228,960.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 17,817 shares of Share Option (right to buy) at $0.34 per share (Derivative)
  Date: 2026-09-01 | Code: M | Expires: 2029-09-10 | equity_swap_involved: 0 | shares_owned_after: 125,081.00 | transaction_form_type: 4 | Footnotes: F1, F3, F4
• Acquired 5,939 shares of American Depositary Shares (Derivative)
  Date: 2026-09-01 | Code: C | equity_swap_involved: 0 | shares_owned_after: 5,939.00 | transaction_form_type: 4 | Footnotes: F5, F6, F5, F5
• Sold 1,300 shares of American Depositary Shares (Derivative)
  Date: 2026-09-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 4,639.00 | transaction_form_type: 4 | Footnotes: F5, F7, F8, F5, F5
• Sold 4,539 shares of American Depositary Shares (Derivative)
  Date: 2026-09-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 100.00 | transaction_form_type: 4 | Footnotes: F5, F7, F8, F5, F5
• Sold 100 shares of American Depositary Shares (Derivative)
  Date: 2026-09-01 | Code: S | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F5, F7, F8, F5, F5

Footnotes:

• F1: Reflects price per share in Ordinary Shares.
• F2: The Ordinary Shares were converted into American Depositary Shares as reported in Table II.
• F3: 1/4 of the Ordinary Shares vested one year after July 22, 2019 (the "Vesting Commencement Date"); the balance of the Ordinary Shares vested in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.
• F4: This reflects the number of Ordinary Shares remaining under the share option following the partial exercise of the share option for 17,817 Ordinary Shares.
• F5: Each American Depositary Share is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The American Depositary Shares have no expiration date.
• F6: 17,817 Ordinary Shares, which were acquired upon exercise of a share option, were converted into 5,939 American Depositary Shares.
• F7: The American Depositary Shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 26, 2026.
• F8: Reflects price per share in American Depositary Shares.
• F9: The weighted average sale price for the transaction reported was $45.8642 and the range of prices were between $45.63 and $46.38. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of American Depositary Shares sold at each price will be provided.
• F10: The weighted average sale price for the transaction reported was $47.2030, and the range of prices were between $46.80 and $47.76. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of American Depositary Shares sold at each price will be provided.